Anna Rose Welch articles

1. Education, Patents, Sustainability, Oh My! Experts Dish On 2020 Biosimilar Challenges 1/15/2020

   In this final installment of the Biosimilar Editorial Board 2020 Outlook series, it's clear there is also a growing urgency and passion for seeing this industry succeed — and that passion is not to be underestimated.

2. Sandoz Executives: Have Biosimilars Lived Up To Their Promise? 1/13/2020

   I had the fortune of talking with two U.S. Sandoz executives, Sheila Frame, VP, marketing, market access, and patient services, and William Yoon, head, external engagement and medical advocacy. In the first of this two-part article, I picked their brains about the progress they’ve observed and how challenges for the industry have evolved over the past 10 years.

3. Biosimilar Industry Advancements To Watch In 2020 1/8/2020

   Multi-biosimilar competition in the U.S. oncology space, as well as the FDA’s regulatory progress toward a more competitive insulin market were popular topics among the whole group. But these are hardly the only big events to note in this progressing industry.

4. Fresenius Kabi: The Quest For More Efficient Biosimilar R&D 1/6/2020

   Following the news of Fresenius Kabi’s new biosimilar R&D lab, I reached out to one executive to discuss the current challenges in biosimilar R&D, including maintaining the delicate balance between biosimilar R&D and commercial teams as Fresenius Kabi prepares for a long future in the biosimilar space.

5. The Top 7 Biosimilar Developments of 2019 12/30/2019

   I normally only do the top five developments for the biosimilar industry in this annual column. But it turned out, upon reflection, that 2019 was an even more eventful year than it may have seemed as we were making our way through. So, you’re getting a whopping seven this year.

6. What Does 2020 Hold For Biosimilars? Industry Experts Weigh In 12/18/2019

   As we face 2020, several big questions remain from the past year and about what the future may (or may not) bring for the industry. Here, these 19 experts pose their biggest questions for the new year, as well as how they anticipate or hope these questions could be answered.

7. Biosimilar Industry Experts Highlight 2019 Triumphs, Tribulations 12/11/2019

   As we close out another year of global biosimilar successes and twists and turns, it’s always important to take stock on just how far we have come and where we still hope to go as an industry. As in years past, I reached out to members of Biosimilar Development’s editorial board and several other experts to get their take on the past year's progress.

8. Inside FDA’s Latest Biosimilar “Game Changing” Guidance 12/9/2019

   Overall, there are three broad takeaways to both celebrate and consider about the FDA’s latest clarification of the biosimilar regulatory pathway as it relates to insulin biosimilars.

9. Biosimilar Competition Is Here To Stay In 2020 12/5/2019

   Following Peter Bach’s controversial argument to “throw in the towel” on biosimilars, I reached out to three economic experts for their perspectives on how to create a functioning, competitive biologics marketplace and which economic and government policies will be the best to pursue for long-term success.

10. The Biologic, Biosimilar Insulin Transition: The Patient Perspective 11/29/2019

    In this article, a patient advocate from the JDRF shares the diabetes community’s perspective on the upcoming regulatory transition of insulins and how the industry can better engage and educate patients about the future presence of insulin biosimilars.